

ASCELIA  
PHARMA

Share ticker: ACE  
Nasdaq Stockholm (small cap)

# ANNUAL GENERAL MEETING 2020

Presentation from CEO

Malmö, 6 May 2020

# ASCELIA PHARMA



Improve **life expectancy** and **quality of life** for people living with cancer



We develop **orphan drugs** which target unmet medical needs, have an established mode of action and a relatively low development risk

| Drug candidate   | Indication   | Phase 1 | Phase 2     | Phase 3   | Register | Launch |
|--|--|---------|-------------|---|----------|--------|
| <b>Mangoral</b> <ul style="list-style-type: none"><li>• Only <u>non</u>-gadolinium imaging drug</li><li>• No competing products</li><li>• \$350-500M market with upside potential</li><li>• De-risked Phase 3 clinical program</li></ul> | <b>Visualisation of focal liver lesions</b> <ul style="list-style-type: none"><li>• Liver metastases</li><li>• Primary liver cancer</li><li>• Benign lesions</li></ul> | ✓       | ✓           | 2020 – Full study report H1 2021                            | 2021     | 2022   |
| <b>Oncoral</b> <ul style="list-style-type: none"><li>• Novel tablet chemotherapy formulation</li><li>• Phase 1 completed with promising results</li><li>• Gastric cancer is an Orphan indication</li></ul>                               | <b>Treatment of gastric cancer</b>   | ✓       | 2021 – 2023 | Partner after Phase 2 for the further development to market |          |        |

# FINANCIAL YEAR 2019 (JUL-DEC 2019) – LAYING THE GROUNDWORK

Jan-Jun  
2019

## Creating the foundation

- Positive feedback from regulatory agencies on Phase 3 program for Mangoral
- Oversubscribed IPO raising SEK 200 million

Jul-Dec  
2019

## Laying the groundwork

- Preparatory work for Phase 3 SPARKLE study
- Opening of study sites for SPARKLE

2020 to  
today

## Delivering

- First patient visit in the pivotal Phase 3 study SPARKLE
- First patient visit in the hepatic study



## Leading Ascelia Pharma through Covid-19

- ▶ We have taken steps to minimise risk for the patients, our employees and their families, and our communities
- ▶ Strong financial position with SEK 184 million in liquid assets per 31 Dec 2019 and a low cost base
- ▶ Our assets Mangoral and Oncoral are strong and fundamentally unchanged. There still is – and will be – a significant unmet medical need and attractive commercial opportunities for these projects
- ▶ A prolonged Corona situation could, however, impact our expected timelines
- ▶ Today's enrollment of the first patient in the hepatic study shows that selected parts of our community is still in operation

## PRIORITIES IN 2020



First patient in the SPARKLE study




First patient in the hepatic study



Work diligently with clinical study sites during Covid-19 and enroll further patients in SPARKLE



Pre-launch activities and preparations for Mangoral (launch planned for 2022)



Prepare for the Phase 2 study for Oncoral (planned to start in 2021)

# ASCELIA PHARMA

[ascelia.com](https://ascelia.com)